Successful treatment of disseminated fusariosis with voriconazole in an acute lymphoblastic leukaemia patient

Mycoses

Volumn 54, Issue SUPPL. 4, 2011, Pages 8-11

  Labois, Aurelie ^a   Gray, Christian ^a   Lepretre, Stephane ^a  

^a Centre de Lutte Contre le Cancer Henri Becquerel   (France)

Author keywords

Acute leukaemia; Disseminated invasive fusariosis; Fusarium (solani); Mould; Voriconazole

Indexed keywords

CASPOFUNGIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROCORTISONE; IMATINIB; IMIPENEM; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VANCOMYCIN; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CONTINUOUS INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FUNGUS ISOLATION; FUSARIOSIS; FUSARIUM SOLANI; HUMAN; LIVER DYSFUNCTION; MYALGIA; NEUTROPENIA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RASH; SHIVERING; SKIN BIOPSY; SUBCUTANEOUS NODULE;

ANTIFUNGAL AGENTS; DRUG THERAPY; FEMALE; FUSARIOSIS; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRIMIDINES; RADIOGRAPHY, THORACIC; SKIN; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 82455175523     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02136.x     Document Type: Article

References (15)

1. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10(Suppl1): 67-75.
2. Ho DY, Lee JD, Rosso F. Treating disseminated fusariosis: amphotericin B, voriconazole or both? Mycoses 2007; 50: 227-31.
3. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704.
4. Anaissie EJ, Kuchar R, Rex JH, Summerbell R, Walsh T. The hospital water system as a reservoir of Fusarium. Abstract J94. 37th Interscience Conference on Antimicrobial Agents Chemotherapy. Toronto, 1997.
5. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14(Suppl 1): 43-53.
6. Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-candida fungal infections following bone marrow transplantation. Medicine 1993; 72: 78-89.
7. Walsh TJ, Anaissie RJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008; 46: 327-60.
8. Lass-Florl C, Mayr CA, Perkhofer S et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2008; 52: 3637-41.
9. Tortorano AM, Prigitano A, Dho G et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. From Northern Italy. Antimicrob Agents Chemother 2008; 52: 2683-5.
10. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer centre and implications for management. Blood 1997; 90: 999-1008.
11. Nucci M, Marr KA, Queiroz-Telles F et al. Fusarium infection in haematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38: 1237-42.
12. Lortholary O, Obenga G, Biswas P et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54: 4446-50.
13. Gupta S, Almyroudis NG, Battiwalla M et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007; 9: 156-60.
14. Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
15. Spellberg B, Schwartz J, Fu Y et al. Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 2006; 58: 973-79.